International Assets Investment Management LLC Has $285,000 Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

International Assets Investment Management LLC cut its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 97.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,207 shares of the company's stock after selling 320,565 shares during the period. International Assets Investment Management LLC's holdings in Ionis Pharmaceuticals were worth $285,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company's stock valued at $27,000 after buying an additional 303 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth approximately $37,000. Capital Performance Advisors LLP acquired a new stake in shares of Ionis Pharmaceuticals during the third quarter worth $40,000. Prospera Private Wealth LLC acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at approximately $42,000. Finally, Quantbot Technologies LP bought a new position in Ionis Pharmaceuticals during the 3rd quarter worth approximately $51,000. 93.86% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. William Blair reaffirmed an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $70.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. Needham & Company LLC reiterated a "buy" rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Wells Fargo & Company dropped their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating on the stock in a report on Thursday, November 7th. Finally, StockNews.com cut shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $60.65.

Ionis Pharmaceuticals Stock Performance

Shares of IONS traded down $0.22 during mid-day trading on Monday, reaching $33.24. The company's stock had a trading volume of 224,151 shares, compared to its average volume of 1,056,865. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals, Inc. has a 1-year low of $32.80 and a 1-year high of $53.17. The business has a 50-day simple moving average of $36.22 and a two-hundred day simple moving average of $41.59. The stock has a market cap of $5.25 billion, a P/E ratio of -13.62 and a beta of 0.35.

Insider Buying and Selling at Ionis Pharmaceuticals

In related news, CEO Brett P. Monia sold 6,630 shares of the business's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the completion of the sale, the chief executive officer now directly owns 167,393 shares in the company, valued at $6,369,303.65. The trade was a 3.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Eric Swayze sold 1,194 shares of the firm's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the transaction, the executive vice president now directly owns 33,713 shares in the company, valued at approximately $1,278,396.96. This represents a 3.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,877 shares of company stock valued at $299,578 in the last quarter. 2.71% of the stock is currently owned by insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.